Nonclassical transpeptidases of Mycobacterium tuberculosis alter cell size, morphology, the cytosolic matrix, protein localization, virulence, and resistance to β-lactams

Journal of Bacteriology

Volumn 196, Issue 7, 2014, Pages 1394-1402

  Schoonmaker, Maia K ^b   Bishai, William R ^b   Lamichhanea, Gyanu ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; ETHAMBUTOL; GAMMA GLUTAMYLTRANSFERASE; ISONIAZID; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; BAGG ALBINO MOUSE; CELL FUNCTION; CELL GROWTH; CELL SHAPE; CELL SIZE; CELL STRUCTURE; CELL SURFACE; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EXTRACELLULAR MATRIX; FEMALE; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TRANSMISSION ELECTRON MICROSCOPY; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMS; CYTOSOL; FEMALE; HUMANS; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PEPTIDYL TRANSFERASES; PROTEIN TRANSPORT; TUBERCULOSIS; VIRULENCE;

EID: 84895735604     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.01396-13     Document Type: Article

References (46)

1. Vollmer W, Holtje JV. 2004. The architecture of the murein (peptidoglycan) in gram-negative bacteria: vertical scaffold or horizontal layer(s)? J. Bacteriol. 186:5978-5987. http://dx.doi.org/10.1128/JB.186.18.5978-59 87.2004.
2. Wietzerbin J, Das BC, Petit JF, Lederer E, Leyh-Bouille M, Ghuysen JM. 1974. Occurrence of D-alanyl-(D)-meso-diaminopimelic acid and mesodiaminopimelyl- meso-diaminopimelic acid interpeptide linkages in the peptidoglycan of mycobacteria. Biochemistry 13:3471-3476. http://dx.doi.org/10.1021/bi00714a008.
3. Crick DC, Brennan PJ. 2008. Biosynthesis of the arabinogalactanpeptidoglycan complex, p 25-40. In Daffe M, Reyrat J (ed), The mycobacterial cell envelope. ASM Press, Washington, DC.
4. Tuomanen E, Cozens R. 1987. Changes in peptidoglycan composition and penicillin-binding proteins in slowly growing Escherichia coli. J. Bacteriol. 169:5308-5310.
5. Caparros M, Pisabarro AG, de Pedro MA. 1992. Effect of D-amino acids on structure and synthesis of peptidoglycan in Escherichia coli. J. Bacteriol. 174:5549-5559.
6. Lavollay M, Arthur M, Fourgeaud M, Dubost L, Marie A, Veziris N, Blanot D, Gutmann L, Mainardi JL. 2008. The peptidoglycan of stationary- phase Mycobacterium tuberculosis predominantly contains crosslinks generated by L, D-transpeptidation. J. Bacteriol. 190:4360-4366. http://dx.doi.org/10.1128/JB.00239-08.
7. Lavollay M, Fourgeaud M, Herrmann JL, Dubost L, Marie A, Gutmann L, Arthur M, Mainardi JL. 2011. The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L, D-transpeptidases. J. Bacteriol. 193:778-782. http://dx.doi.org/10.1128/JB.00606-10.
8. Kumar P, Arora K, Lloyd JR, Lee IY, Nair V, Fischer E, BoshoffHI, Barry CE, III. 2012. Meropenem inhibits D, D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol. Microbiol. 86:367-381. http://dx.doi.org/10.1111/j.1365-2958.2012.08199.x.
9. Goffin C, Ghuysen JM. 2002. Biochemistry and comparative genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent. Microbiol. Mol. Biol. Rev. 66: 702-738. http://dx.doi.org/10.1128/MMBR.66.4.702-738.2002.
10. Flores AR, Parsons LM, Pavelka MS, Jr. 2005. Characterization of novel Mycobacterium tuberculosis and Mycobacterium smegmatis mutants hypersusceptible to beta-lactam antibiotics. J. Bacteriol. 187:1892-1900. http://dx.doi.org/10.1128/JB.187.6.1892-1900.2005.
11. Tuomanen E, Cozens R, Tosch W, Zak O, Tomasz A. 1986. The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. J. Gen. Microbiol. 132:1297-1304.
12. Walsh C. 2003. Antibiotics: actions, origins, resistance. ASM Press, Washington, DC.
13. Mainardi JL, Fourgeaud M, Hugonnet JE, Dubost L, Brouard JP, Ouazzani J, Rice LB, Gutmann L, Arthur M. 2005. A novel peptidoglycan cross-linking enzyme for a beta-lactam-resistant transpeptidation pathway. J. Biol. Chem. 280:38146-38152. http://dx.doi.org/10.1074/jbc. M507384200.
14. Bielnicki J, Devedjiev Y, Derewenda U, Dauter Z, Joachimiak A, Derewenda S. 2006. B. subtilis ykuD protein at 2.0 A resolution: insights into the structure and function of a novel, ubiquitous family of bacterial enzymes. Proteins 62:144-151. http://dx.doi.org/10.1002/prot.20702.
15. Biarrotte-Sorin S, Hugonnet JE, Delfosse V, Mainardi JL, Gutmann L, Arthur M, Mayer C. 2006. Crystal structure of a novel beta-lactaminsensitive peptidoglycan transpeptidase. J. Mol. Biol. 359:533-538. http://dx.doi.org/10.1016/j.jmb.2006.03.014.
16. Mt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16:466-469. http://dx.doi.org/10.1038/nm.2120.
17. Peltier J, Courtin P, El Meouche I, Lemee L, Chapot-Chartier MP, Pons JL. 2011. Clostridium difficile has an original peptidoglycan structure with a high level of N-acetylglucosamine deacetylation and mainly 3-3 cross-links. J. Biol. Chem. 286:29053-29062. http://dx.doi.org/10.1074/jbc. M111.259150.
18. Sanders AN, Pavelka MS. 2013. Phenotypic analysis of E. coli mutants lacking L, D-transpeptidases. Microbiology 159:1842-1852. http://dx.doi.org/10.1099/mic.0.069211-0.
19. Erdemli SB, Gupta R, Bishai WR, Lamichhane G, Amzel LM, Bianchet MA. 2012. Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L, D-transpeptidase 2. Structure 20:2103-2115. http://dx.doi.org/10.1016/j.str.2012.09.016.
20. Mt2, an L, D-transpeptidase from Mycobacterium tuberculosis. Acta Crystallogr. D Biol. Crystallogr. 69:432-441. http://dx.doi.org/10.1107/S0907444912049268.
21. Kim HS, Kim J, Im HN, Yoon JY, An DR, Yoon HJ, Kim JY, Min HK, Kim SJ, Lee JY, Han BW, Suh SW. 2013. Structural basis for the inhibition of Mycobacterium tuberculosis L, D-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains. Acta Crystallogr. D Biol. Crystallogr. 69:420-431. http://dx.doi.org/10.1107/S0907444912 048998.
22. Mt2 in complex with meropenem reveals the mechanism of carbapenem against Mycobacterium tuberculosis. Cell Res. 23:728-731. http://dx.doi.org/10.1038/cr.2013.53.
23. Mt1 from Mycobacterium tuberculosis. Acta Crystallogr. D Biol. Crystallogr. 69:1697-1706. http://dx.doi.org/10.1107/S0907444913013085.
24. Cordillot M, Dubee V, Triboulet S, Dubost L, Marie A, Hugonnet JE, Arthur M, Mainardi JL. 2013. In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L, D-transpeptidases and inactivation of these enzymes by carbapenems. Antimicrob. Agents Chemother. 57: 5940-5945. http://dx.doi.org/10.1128/AAC.01663-13.
25. Valway SE, Sanchez MP, Shinnick TF, Orme I, Agerton T, Hoy D, Jones JS, Westmoreland H, Onorato IM. 1998. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N. Engl. J. Med. 338:633-639. http://dx.doi.org/10.1056/NEJM19980305 3381001.
26. Barkan D, Rao V, Sukenick GD, Glickman MS. 2010. Redundant function of cmaA2 and mmaA2 in Mycobacterium tuberculosis cis cyclopropanation of oxygenated mycolates. J. Bacteriol. 192:3661-3668. http://dx.doi.org/10.1128/JB.00312-10.
27. Lee MH, Pascopella L, Jacobs WR, Jr, Hatfull GF. 1991. Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc. Natl. Acad. Sci. U. S. A. 88:3111-3115. http://dx.doi.org/10.1073/pnas.88.8.3111.
28. Hatfull GF, Jacobs WR, Jr. 2000. Some common methods in mycobacterial genetics, p 313-320. In Hatfull GF, Jacobs WR, Jr (ed), Molecular genetics of mycobacteria. ASM Press, Washington, DC.
29. Manganelli R, Dubnau E, Tyagi S, Kramer FR, Smith I. 1999. Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis. Mol. Microbiol. 31:715-724. http://dx.doi.org/10.1046/j.1365-2958.1999.01212.x.
30. Cynamon MH, Speirs RJ, Welch JT. 1998. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob. Agents Chemother. 42: 462-463.
31. Paul TR, Beveridge TJ. 1993. Ultrastructure of mycobacterial surfaces by freeze-substitution. Zentralbl. Bakteriol. 279:450-457. http://dx.doi.org/10.1016/S0934-8840(11)80416-0.
32. Hingley-Wilson SM, Sambandamurthy VK, Jacobs WR, Jr. 2003. Survival perspectives from the world's most successful pathogen, Mycobacterium tuberculosis. Nat. Immunol. 4:949-955. http://dx.doi.org/10.1038/ni981.
33. Van Heijenoort J. 1996. Murein synthesis, p 1025-1034. In Neidhardt FC, Curtiss R, III, Ingraham JL, Lin ECC, Low KB, Magasanik B, ReznikoffWS, Riley M, Schaechter M, Umbarger HE (ed), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed. ASM Press, Washington, DC.
34. Meroueh SO, Bencze KZ, Hesek D, Lee M, Fisher JF, Stemmler TL, Mobashery S. 2006. Three-dimensional structure of the bacterial cell wallpeptidoglycan. Proc. Natl. Acad. Sci. U. S. A. 103:4404-4409. http://dx.doi.org/10.1073/pnas.0510182103
35. Barksdale L, Kim KS. 1977. Mycobacterium. Bacteriol. Rev. 41:217-372.
36. Neyrolles O, Hernandez-Pando R, Pietri-Rouxel F, Fornes P, Tailleux L, Barrios Payan JA, Pivert E, Bordat Y, Aguilar D, Prevost MC, Petit C, Gicquel B. 2006. Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS One 1:e43. http://dx.doi.org/10.1371/journal.pone.0000043.
37. Malen H, Berven FS, Fladmark KE, Wiker HG. 2007. Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv. Proteomics 7:1702-1718. http://dx.doi.org/10.1002/pmic.200600853.
38. Covert BA, Spencer JS, Orme IM, Belisle JT. 2001. The application of proteomics in defining the T cell antigens of Mycobacterium tuberculosis. Proteomics 1:574-586. http://dx.doi.org/10.1002/1615-9861(200104)1 :4<574::AID-PROT574>3.0.CO;2-8.
39. Malen H, Softeland T, Wiker HG. 2008. Antigen analysis of Mycobacterium tuberculosis H37Rv culture filtrate proteins. Scand. J. Immunol. 67:245-252. http://dx.doi.org/10.1111/j.1365-3083.2007.02064.x.
40. Mattow J, Schaible UE, Schmidt F, Hagens K, Siejak F, Brestrich G, Haeselbarth G, Muller EC, Jungblut PR, Kaufmann SH. 2003. Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M. bovis BCG Copenhagen. Electrophoresis 24:3405-3420. http://dx.doi.org/10.1002/elps.200305601.
41. de Souza GA, Leversen NA, Malen H, Wiker HG. 2011. Bacterial proteins with cleaved or uncleaved signal peptides of the general secretory pathway. J. Proteomics 75:502-510. http://dx.doi.org/10.1016/j.jprot.2011.08.016.
42. Kastrinsky DB, Barry CE. 2010. Synthesis of labeled meropenem for the analysis of M. tuberculosis transpeptidases. Tetrahedron Lett. 51:197-200. http://dx.doi.org/10.1016/j.tetlet.2009.10.124.
43. Mt1 by carbapenems and cephalosporins. Antimicrob. Agents Chemother. 56:4189-4195. http://dx.doi.org/10.1128/AAC.00665-12.
44. Hugonnet JE, Tremblay LW, BoshoffHI, Barry CE, III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 323:1215-1218. http://dx.doi.org/10.1126/science.1167498.
45. Mainardi JL, Hugonnet JE, Gutmann L, Arthur M. 2011. Fighting resistant tuberculosis with old compounds: the carbapenem paradigm. Clin. Microbiol. Infect. 17:1755-1756. http://dx.doi.org/10.1111/j.1469-0691.2011.03699.x.
46. England K, BoshoffHI, Arora K, Weiner D, Dayao E, Schimel D, Via LE, Barry CE, III. 2012. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 56:3384-3387. http://dx.doi.org/10.1128/AAC.05690-11.